Therapy Name | LY294002 |
Therapy Description |
LY294002 is a specific inhibitor of PI3K alpha, beta, and delta, which leads to inhibition of PI3K-Akt/PKB signaling (PMID: 12060641). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
LY294002 | PI3K Inhibitor (Pan) 34 | LY294002 is a specific inhibitor of PI3K alpha, beta, and delta, which leads to inhibition of PI3K-Akt/PKB signaling (PMID: 12060641). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References | KRAS G12D | Advanced Solid Tumor | sensitive | LY294002 | Preclinical | Actionable | In a preclinical study, LY294002 reduced phosphorylation of Akt in pancreatic epithelial cells expressing Kras G12D (PMID: 22871572). | 22871572 |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status |
---|